Huw Jones

CEO, Evgen Pharma PLC

Huw joined the OBN Board in April 2022. He has been CEO of Evgen Pharma PLC, a clinical stage cancer and inflammation company, since October 2020. Huw recently led the raise of £10m in a placing and up to a further £1m in an open offer in a transformative deal for Evgen. He is also a non-executive director of Ixaka Ltd (formerly Rexgenero) a cell and gene therapy company with operations in London, Paris and Seville; Non-executive Chairman of Chronos Therapeutics Ltd in Oxford, and strategic advisor to Gen2 Neuroscience in Cambridge, an antibody company focussed on tauopaties such as Alzheimer’s Disease.

During his time at Chronos, Huw extracted the company from Oxford University, raised tens of millions in grant and equity finance and led Chronos’ acquisition of three early research programmes in brain disease from Shire PLC. He was surprised and pleased to have been awarded European CEO of the year 2016/17 for drug discovery by European CEO Magazine, alongside leaders in their sectors from Adidas, Unilever and Spotify.

Huw's previous posts include: Non-Executive Director, then rescue CEO, Ardana PLC; non–executive chairman of private equity owned Ashbourne Pharmaceuticals; president Europe for NASDAQ listed CV Therapeutics Inc; SVP Europe, Elan Pharmaceuticals and various roles of increasing responsibility at SmithKline Beecham (GSK). In his varied career he has launched dozens of new medicines in several countries, completed tens of M&A transactions and managed many drug development programmes.

A native of south west Wales, Huw has a degree in pharmacology from Cardiff University and a PhD in neuropharmacology from the University of Birmingham. In addition to speaking at industry events as a speaker or panel member, he is occasionally called upon to comment on healthcare matters in Welsh on both S4C and Radio Cymru.

Huw is a passionate rugby union supporter, enjoys SCUBA diving, cycling and wine appreciation.